New combo therapy trial aims to boost immune attack on advanced breast cancer
NCT ID NCT03393845
Summary
This study is testing whether adding an immunotherapy drug (pembrolizumab) to a standard hormone-blocking drug (fulvestrant) can better control advanced breast cancer that has spread. It enrolled 47 adults whose cancer is fueled by hormones but not by the HER2 protein, and who have had few prior treatments. The main goal is to see if the combination helps shrink tumors or keep the cancer from growing for a longer time.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Michigan State University, Breslin Cancer Center
Lansing, Michigan, 48910, United States
-
New York University Clinical Cancer Center
New York, New York, 10016, United States
-
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, 08903, United States
-
University of Nebraska Medical Center
Omaha, Nebraska, 68198, United States
-
University of Wisconsin
Madison, Wisconsin, 53705, United States
Conditions
Explore the condition pages connected to this study.